Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 7/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779962 | 0.89 | PTPRB (0.51) | PTPRBESR1ESR2PPARGPPARD | |
| SCHEMBL6506722 | 0.82 | ESR1 (0.62) | PTPRBESR1ESR2PPARGPPARD | |
| SCHEMBL3779421 | 0.81 | NOS2 (0.48) | PTPRBESR1ESR2PPARGPPARD | |
| SCHEMBL5452680 | 0.80 | MMP8 (0.55) | PTPRBPPARGPPARDPPARA | |
| SCHEMBL17479471 | 0.78 | PTPRB (0.46) | PTPRBESR1ESR2PPARGPPARD | |
| SCHEMBL3781692 | 0.78 | ALDH1A1 (0.59) | — | |
| SCHEMBL3780615 | 0.77 | MMP8 (0.46) | PTPRB | |
| SCHEMBL3783037 | 0.75 | ENPP2 (0.42) | LDHA | |
| SCHEMBL18931725 | 0.75 | PTPRB (0.46) | PTPRBESR1ESR2PPARGPPARD | |
| SCHEMBL19953751 | 0.75 | PTPRB (0.55) | PTPRBESR1ESR2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | PTPRB 1100/4885PSIP1 3066/4885ESR1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.